Shugeng Cao, PhD

Shugeng Cao, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 932-8125 | Lab Web Page

Associate Member, Cancer Biology Program, University of Hawaiʻi Cancer Center

Academic Appointment(s):
Professor, The Daniel K. Inouye College of Pharmacy, University of Hawaiʻi at Hilo

PhD, Organic Chemistry, National University of Singapore
Post-doctorate, Virginia Tech & Harvard Medical School

Research Focus

Nature has been a rich source for drug discovery for centuries. Many anticancer drugs were developed from plant metabolites. However, microorganisms from plants, oceans and insects etc. are underexplored natural sources for anticancer drug discovery. (i) It is well known that bacteria are producers of variety of bioactive compounds. But it is fair to say that no single strain has been entirely studied for its secondary metabolites; and not much attention has been paid to some bacteria (for example, deep-sea bacteria, bacteria associated with arthropods, and bacteria from lower animals etc.) that are therefore, underexplored for their bioactive compounds. (ii) Each of the about 250,000 land plant species hosts one or more endophytes. An endophyte could be either a bacterium or a fungus. Endophytic fungi have been studied, but few of these endophytes have been characterized, and they are very underexplored for their secondary metabolites when compared to fungal plant pathogens and fungal soil isolates. (iii) Oceans cover nearly 70% of the earth's surface and possess nearly 300,000 described species of plants and animals from marine sources, comprising about half of the total biodiversity. However, the development of marine natural products as therapeutic agents is still in its early stages due to the lack of an analogous ethno-medical history as compared to terrestrial habitats, together with the relative technical difficulties in collecting the marine floral samples. On the other hand, microorganisms can grow in almost all marine habitats, for example, coral, algae, sponges, fishes and sediments etc., but they are underexplored. Hence, microorganisms in the marine environment are also an extremely rich source for anticancer drug discovery.

The Cao laboratory focuses on exploring bacteria, endophytic fungi and marine-associated microorganisms for anticancer drug discovery. This will be carried out through collaboration between different disciplines at the UH Cancer Center with novel approaches to guide the identification of strains that have the potential to produce anticancer drug leads; novel dereplication technique (e.g., LC/MS etc.) to identify strains that produce novel compounds; structure elucidation of active compounds by NMR, chemical modifications and degradations, and x-ray analysis; high throughput screening through collaboration with oncologists; and genome sequencing if necessary.

The Cao Lab also works on herbal medicines used for diseases related to cancer and diabetes, etc., and small molecules with various biological functions in bacteria and the human body.

Selected Publications

Koher G, Khan A, Suarez-Vega G, Meesakul P, Bacani AJ, Kohno T, Zhu X, Kim KH, Cao* S, Jia* Z. (2023). "A Comprehensive Insight into Māmaki (Pipturus albidus): Its Ethnomedicinal Heritage, Human Health Research, and Phytochemical Properties." Plants (Basel). Aug 12;12(16):2924.

Li L, Wang Y, Chen N, Li X, Li H, Jin L, Ou Y, Kong XJ, Cao S, Xu Q, Wu X, Han J, Deng X. (2023). “Exploring Diversity through Dimerization in Natural Products by a Rational Tandem Mass-Based Molecular Network Strategy.” Org Lett; 25(22), 4016-4021.

Xu S, Liu Y-X, Wang H, Cao S, Zhou Y, Cernava T, Berg G, Xia T, Shen X-X, Wen Z, Xiao Y, Li C, Qu B, Ruan H, Chai Y, Zhou X, Ma Z, Shi Y, Yu* Y, Bai* Y, Chen* Y. (2022). “Bacteria within fungal fruiting-body microbiome protect crops against fungal infections by disrupting lipid rafts” Nature Microbiology; 7(6):831-843.

Freckelton ML, Nedved BT, Cai Y-S, Cao S, Turano H, Alegado RA, Hadfield* MG. (2022). “Bacterial lipopolysaccharide induces settlement and metamorphosis in a marine larva.” Proc. Natl. Acad. Sci.; 119(18), e2200795119.

Li C, Hu Y, Wu X, Stumpf SD, Qi Y, D’Alessandro JM, Nepal KK, Sarottid AM, Cao* S, Joshua AV Blodgettc* JAV. (2022). “Discovery of unusual dimeric piperazyl cyclopeptides encoded by a Lentzea flaviverrucosa DSM 44664 biosynthetic supercluster” Proc. Natl. Acad. Sci.; 119(17), e2117941119.

Publication list via PubMed

Active Grants

S. Cao, Investigator (PI: Huang)
NIH R01 AI173245-01A1
“M. tuberculosis metabolites to activate human mucosal-associated invariant T cells”
07/01/2023 – 06/30/2028

S. Cao, PI (Co-investigators: Cowie and Gosnell)
NIH R21 AI178354-01
“Antiparasitic Agent Discovery from Microorganisms in Hawaii for the Treatment of a Globally Emerging Disease”
08/01/2023 – 07/31/2025

S. Cao, PI
Hawaii Community Foundation
“From genomes to antibiotic drug discovery from Hawaiian volcanic fungi”
05/2023 – 11/2024

S. Cao, Investigator (PI: Hoffmann)
INBRE-Rain (Regional Alliance of INBRE Networks)
“Target identification of Petrichorin A”
2023 – 2024